Papers
1
Total Citations
2
H-Index
1
About
Xinyu Bi is a clinical researcher whose work focuses on improving outcomes for patients with hepatocellular carcinoma (HCC), particularly those at high risk of recurrence. Her key research areas include perioperative treatment strategies, immunotherapy combinations, and targeted therapy in liver cancer. Bi’s most notable contribution is a prospective, single-arm, phase Ib study evaluating TQB2450, a PD-L1 blockade, combined with anlotinib as a perioperative treatment for high-risk HCC patients. This work, published in 2023, has already garnered 2 citations, signaling early recognition of its potential to shift clinical practice. By exploring the synergy between immune checkpoint inhibition and anti-angiogenic therapy, Bi addresses a critical unmet need—reducing recurrence after surgery. Her research exemplifies the growing trend toward integrating novel systemic therapies into the perioperative setting, offering hope for more durable responses. As a rising voice in oncology, Bi’s work bridges translational science and clinical application, making her a researcher to watch in the evolving landscape of liver cancer management.
Research Focus
Key Achievements
Top Papers
- 1